Prognostic significance of systemic immunoinflammatory biomarkers and pathological features in clear cell renal cell carcinoma: a multicenter study.

Ann MedAug 30, 2026 (epub)
Clinical ResearchOncology (Medical)UrologyOpen access

Zhenduo Yu, Junfeng Yang, Xinyang Lv et al.

✦ AI-curated · Sources linked

In 30 seconds

This multicenter retrospective study evaluated systemic immunoinflammatory biomarkers and pathological features to develop a prognostic model for overall survival (OS) in clear cell renal cell carcinoma (ccRCC). Among 1,635 patients, ISUP grade, tumor necrosis, platelet count, recurrence/metastasis status, and systemic inflammation response index (SIRI) were independently associated with OS. The nomogram achieved C-indices of 0.849 and 0.869.

Key findings

  • ISUP grade, tumor necrosis, and platelet count were independently associated with overall survival.
  • The nomogram demonstrated C-indices of 0.849 in the training cohort and 0.869 in the internal testing cohort.
  • 1-, 3-, and 5-year AUCs ranged from 0.829 to 0.897, indicating strong predictive performance.
  • Risk stratification identified groups with significantly different survival outcomes (p < 0.001).

Why it matters

Understanding the prognostic significance of immunoinflammatory biomarkers and pathological features can help clinicians better predict outcomes in ccRCC patients, potentially guiding treatment decisions and follow-up strategies.

Source

PubMed · PMID 42669053Free full text on PubMed Central

Published in Ann Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.